Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alkaloid AD SkopjeXMAE:ALK 100 EV-to-EBITDA is 15.66 as of Aug. 13, 2026, which is 8% above its 10-year median of 14.56. GuruFocus rates XMAE:ALK with a GF Score™ of 100/100 and a GF Value™ of MKD26,980.59 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 734 Drug Manufacturers companies, Alkaloid AD Skopje ranks worse than 57.49% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alkaloid AD Skopje's enterprise value is MKD35,685 Mil.
Alkaloid AD Skopje's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was MKD2,278 Mil. Therefore, Alkaloid AD Skopje's EV-to-EBITDA for today is 15.66.
The historical rank and industry rank for Alkaloid AD Skopje's EV-to-EBITDA or its related term are showing as below:
XMAE:ALK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.88 Med: 14.56 Max: 22.89
Current: 15.66
During the past 13 years, the highest EV-to-EBITDA of Alkaloid AD Skopje was 22.89. The lowest was 8.88. And the median was 14.56.
XMAE:ALK's EV-to-EBITDA is ranked worse than 57.49% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.355
vs XMAE:ALK: 15.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Alkaloid AD Skopje (XMAE:ALK) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alkaloid AD Skopje's PE Ratio (TTM) for today is calculated as:
Alkaloid AD Skopje's share price for today is MKD23000.00.
Alkaloid AD Skopje's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MKD1299.381.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Alkaloid AD Skopje's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAE:ALK vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alkaloid AD Skopje's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkaloid AD Skopje EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkaloid AD Skopje's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alkaloid AD Skopje's EV-to-EBITDA falls into.
Alkaloid AD Skopje's current Enterprise Value is MKD35,685 Mil.
Alkaloid AD Skopje's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MKD2,278 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkaloid AD Skopje (XMAE:ALK) has a EV-to-EBITDA of 15.66 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alkaloid AD Skopje. This is near median its historical median of 14.56. Over the past decade, Alkaloid AD Skopje's EV-to-EBITDA has ranged from 8.88 to 22.89. According to the industry distribution chart, Alkaloid AD Skopje ranks #422 out of 734 companies in the Drug Manufacturers industry, placing it in the top 57.5%.
Is Alkaloid AD Skopje's EV-to-EBITDA too high?
Alkaloid AD Skopje's current EV-to-EBITDA of 15.66 is near median its 10-year median of 14.56. Over the past 10 years, this metric has ranged from a low of 8.88 to a high of 22.89. The Drug Manufacturers industry median EV-to-EBITDA is 13.36. Alkaloid AD Skopje's value of 15.66 is 17.3% above this industry median. Based on the distribution chart, Alkaloid AD Skopje ranks #422 out of 734 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alkaloid AD Skopje has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkaloid AD Skopje's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alkaloid AD Skopje ranks #422 out of 734 companies for EV-to-EBITDA. This places Alkaloid AD Skopje in the lower half of its industry. The industry median EV-to-EBITDA is 13.36. Alkaloid AD Skopje's value of 15.66 is 17.3% above this benchmark. Historically, Alkaloid AD Skopje's own EV-to-EBITDA has ranged from 8.88 to 22.89 over the past decade. While the company's 10-year median is 14.56 vs. the industry median of 13.36, Alkaloid AD Skopje has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.36, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkaloid AD Skopje's current EV-to-EBITDA of 15.66 is 17.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alkaloid AD Skopje. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkaloid AD Skopje's current EV-to-EBITDA is 15.66, which is near median its own 10-year median of 14.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkaloid AD Skopje stock overvalued right now?
Based on GuruFocus' analysis, Alkaloid AD Skopje (XMAE:ALK) is currently considered Modestly Undervalued. The stock's GF Value™ is MKD26,980.59, compared to a current price of MKD23,000.00 — trading 14.8% below its estimated fair value. The current EV-to-EBITDA is 15.66, which is near median its 10-year median of 14.56 and 17.3% above the Drug Manufacturers industry median of 13.36. Alkaloid AD Skopje's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alkaloid AD Skopje (XMAE:ALK), the current EV-to-EBITDA is 15.66 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkaloid AD Skopje (XMAE:ALK) Overvalued in 2026?
Based on GuruFocus' analysis, Alkaloid AD Skopje stock appears to be undervalued.
The current stock price of MKD23,000.00 is trading 14.8% below its estimated GF Value™ of MKD26,980.59.
GuruFocus considers Alkaloid AD Skopje to be Modestly Undervalued.
Key valuation signals for XMAE:ALK:
EV-to-EBITDA: 15.66 (near median its 10-year median of 14.56)
GF Value™: MKD26,980.59 vs. price of MKD23,000.00 (14.8% below fair value)
Industry Position: 17.3% above the Drug Manufacturers median (#422 of 734)
No single metric tells the full story. See the XMAE:ALK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.
100GF Score
Get the complete analysis for XMAE:ALK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAE:ALK has been successfully added to your 
